Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
Brigatinib治疗克唑替尼耐药的ALK+非小细胞肺癌的长期疗效和安全性:1/2期和随机2期(ALTA)试验的最终结果
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2022.100385
Gettinger, Scott N; Huber, Rudolf M; Kim, Dong-Wan; Bazhenova, Lyudmila; Hansen, Karin Holmskov; Tiseo, Marcello; Langer, Corey J; Paz-Ares Rodríguez, Luis G; West, Howard L; Reckamp, Karen L; Weiss, Glen J; Smit, Egbert F; Hochmair, Maximilian J; Kim, Sang-We; Ahn, Myung-Ju; Kim, Edward S; Groen, Harry J M; Pye, Joanna; Liu, Yuyin; Zhang, Pingkuan; Vranceanu, Florin; Camidge, D Ross